Oramed Pharmaceuticals (NASADAQ-OTC: ORMP.OB) was established in 2006, and is based on over 25 years of medical research at the world-renowned Hadassah University Medical Center in Jerusalem, Israel.

For over two decades, scientists at Hadassah Hospital's Diabetes Unit, led by Professor Hanoch Bar-On, worked to develop a technology designed to enable the oral administration of insulin to diabetics.  A medical breakthrough in 2005 laid the foundation for the founding of Oramed Pharmaceuticals, of which Hadassah remains a part owner of the company.  Professor Bar-On helped found Oramed, together with Dr. Miriam Kidron, and served as a director until his untimely death in 2006.

Over the past two years, Oramed has successfully conducted various animal studies with its oral insulin product, ORMD 0801.  The positive outcome set the stage for Phase 1a Phase 1b clinical trials that tested the research on healthy human volunteers, again culminating in successful results. 

In August 2008, Oramed completed Phase 2a clinical trials of ORMD 0801. The goal of these trials was to evaluate the safety and efficacy of oral insulin on individuals diagnosed with diabetes.  These trials proved, for the first time, that Oramed's oral insulin capsule can be effectively delivered to people diagnosed with diabetes.  The trial demonstrated that the product had a good safety profile, was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes. By administering oral insulin to these patients as an earlier form of treatment, patients will be better able to control and balance their diabetes, leading to a healthier condition and better quality of life. 

In May 2010, Oramed completed a  Phase 2b clinical trial in South Africa. These trials tested Oramed's first indication on Type 2 Diabetic patients.

Oramed's is also working on an oral method for delivery of GLP1 analog (ORMD-0901). Oramed's unique oral delivery technology serves as a platform for other vaccines and medications currently available exclusively in injection form.